Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | Director · CHIEF EXECUTIVE OFFICER | February 25, 2021 | February 27, 2021 |
| Radius Health, Inc.RDUS · Entity 124173 | Chief Development Officer | February 13, 2018 | February 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date February 25, 2021 · Filed February 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,629 |
Ending reported balance
After 2021-02-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-25 · Exercise / conversion · Acquired 50,000 · Balance 59,989 F1: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. Row 2 · 2021-02-25 · Tax withholding · Disposed 15,360 · Balance 44,629 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 150,000 |
Reported balance
After 2021-02-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-25 · Exercise / conversion · Disposed 50,000 · Balance 150,000 F1: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4: The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
F4: The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances.
Radius Health, Inc.
Report date February 13, 2018 · Filed February 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.83 · Expires 2028-02-12 | Direct | 60,000 |
Reported balance
After 2018-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-13 · Grant · Acquired 60,000 · Balance 60,000 F1: 25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2021 Filed Feb 27, 2021 00:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001000 · form4-02262021_070201.xml · derivative · entry 3 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| February 25, 2021 Filed Feb 27, 2021 00:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 15,360 | $3.95 | $60,672.00 |
DisclosureSEC source: 0001415889-21-001000 · form4-02262021_070201.xml · nonDerivative · entry 2 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,629 Read SEC document |
| February 25, 2021 Filed Feb 27, 2021 00:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001000 · form4-02262021_070201.xml · nonDerivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:38 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 300,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000734 · form4-02172021_030201.xml · derivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-02-12 F1 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 12, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000502 · form4-02022021_040206.xml · derivative · entry 3 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 643 | $3.44 | $2,211.92 |
DisclosureSEC source: 0001415889-21-000502 · form4-02022021_040206.xml · nonDerivative · entry 2 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,989 F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000502 · form4-02022021_040206.xml · nonDerivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002521 · form4-11022020_041107.xml · derivative · entry 3 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 625 | $2.53 | $1,581.25 |
DisclosureSEC source: 0001415889-20-002521 · form4-11022020_041107.xml · nonDerivative · entry 2 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,757 F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002521 · form4-11022020_041107.xml · nonDerivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001980 · form4-07312020_040702.xml · derivative · entry 3 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 576 | $2.84 | $1,635.84 |
DisclosureSEC source: 0001415889-20-001980 · form4-07312020_040702.xml · nonDerivative · entry 2 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,507 F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001980 · form4-07312020_040702.xml · nonDerivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001105 · form4-05012020_050506.xml · derivative · entry 3 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 577 | $2.92 | $1,684.84 |
DisclosureSEC source: 0001415889-20-001105 · form4-05012020_050506.xml · nonDerivative · entry 2 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,208 F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001105 · form4-05012020_050506.xml · nonDerivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:03 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-20-000501 · form4-02262020_040214.xml · derivative · entry 2 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. F4 · derivative.expiration_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:03 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 400,000 | Not disclosed Strike: $3.59 | Not disclosed |
DisclosureSEC source: 0001415889-20-000501 · form4-02262020_040214.xml · derivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-02-25 F2 · price: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 25, 2021, and the remainder vesting in twelve equal quarterly installments thereafter. F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 25, 2021, and the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000197 · form4-01312020_050112.xml · derivative · entry 3 Williams Gregory C. · CIK 0001597293 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 2,590 | $3.91 | $10,126.90 |
DisclosureSEC source: 0001415889-20-000197 · form4-01312020_050112.xml · nonDerivative · entry 2 Williams Gregory C. · CIK 0001597293 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 F1 · price: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000197 · form4-01312020_050112.xml · nonDerivative · entry 1 Williams Gregory C. · CIK 0001597293 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000637 · form4a-03042020_020307.xml · derivative · entry 3 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER · FORMER CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · shares: The original Form 4 filed on January 31, 2020 is amended by this Form 4 amendment to correctly identify the nature of the transaction of the reporting person. F4 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F1 · derivative.expiration_date: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F5 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 2,590 | $3.91 | $10,126.90 |
DisclosureSEC source: 0001415889-20-000637 · form4a-03042020_020307.xml · nonDerivative · entry 2 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER · FORMER CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000637 · form4a-03042020_020307.xml · nonDerivative · entry 1 Williams Gregory C. · CIK 0001597293 · Director · CHIEF EXECUTIVE OFFICER · FORMER CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0001415889-19-001016 · form4-09132019_040902.xml · derivative · entry 1 Williams Gregory C. · CIK 0001597293 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2029-09-12 F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on September 12, 2020, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 01:25 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000117 · form4-01312019_050137.xml · derivative · entry 2 Williams Gregory C. · CIK 0001597293 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. F4 · derivative.expiration_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 01:25 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $11.53 | $0.00 |
DisclosureSEC source: 0001415889-19-000117 · form4-01312019_050137.xml · derivative · entry 1 Williams Gregory C. · CIK 0001597293 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-30 F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 00:53 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $18.84 | $0.00 |
DisclosureSEC source: 0001209191-18-039558 · doc4.xml · derivative · entry 1 Williams Gregory C. · CIK 0001597293 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: One third (1/3) of the shares underlying the option shall vest on June 25, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each quarterly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 19:49 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $37.83 | $0.00 |
DisclosureSEC source: 0001209191-18-010557 · doc4.xml · derivative · entry 1 Williams Gregory C. · CIK 0001597293 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-02-12 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 16:31 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-17-013277 · doc4.xml · derivative · entry 1 Williams Gregory C. · CIK 0001597293 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-02-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.